About Supreem Pharmaceuticals Mysore Private Limited
Data last updated:
Supreem Pharmaceuticals Mysore Private Limited is a private limited company based in Nanjangudu, Karnataka, India. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 16 August 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24231KA1996PTC020988. Its GSTIN is 29AABCC9895R1ZF (Karnataka). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹5.5 Cr and a paid-up capital of ₹3.94 Cr. It was formerly known as Candor Laboratories Limited and Candor Labs Private Limited. It is led by directors including Sadanand Nagaraja Rao (Managing Director) and Geetha Sadananda Nagaraja Rao (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at # 73 74 & 48P1 KIADB Industrial Area, Nanjangudu, Karnataka, India – 571302.
As per the financials filed for FY 2025, the company reported a revenue of ₹82.17 Cr, a growth of 21% compared to the previous year. For the same year it recorded a net profit of ₹2.28 Cr (net margin 2.8%) and EBITDA of ₹7.24 Cr (EBITDA margin 8.8%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 11% over five years.
The company has about 145 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Supreem Pharmaceuticals. As per MCA filings, the company has open charges of ₹44.24 Cr and satisfied charges of ₹6.7 Cr on record. Court records list 11 cases involving the company, including 8 filed by the company and 3 filed against it; 1 case is pending. The company has 15 deals on record (8 secondary share transfers, 4 rights issues, 3 funding rounds), with disclosed funding of ₹1.85 Cr; the latest was in March 2024. Its 5 peer companies in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 2 smaller; the largest is Nagarjuna Herbal Concentrates Ltd with revenue of ₹83.43 Cr. The company has 6 MSME Form 1 returns on record between 2019 and 2024, listing 69 overdue payments to 21 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website supreempharma.in.
Company details
Name history
Supreem Pharmaceuticals Mysore has undergone 2 name changes throughout its history. The company was previously known as Candor Laboratories Limited, and Candor Labs Private Limited.. The current legal name is Supreem Pharmaceuticals Mysore Private Limited.
| Company Name | Status |
|---|---|
| Supreem Pharmaceuticals Mysore Private Limited | Current |
| Candor Laboratories Limited | Previous |
| Candor Labs Private Limited. | Previous |
CIN history
Supreem Pharmaceuticals Mysore has one previous CIN (Corporate Identification Number): U24231KA1996PLC020988. The current CIN is U24231KA1996PTC020988, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231KA1996PTC020988 | Current |
| U24231KA1996PLC020988 | Previous |
Contact details
Supreem Pharmaceuticals Mysore Private Limited's registered office is in Nanjangudu, Karnataka. Its website is supreempharma.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address# 73 74 & 48P1 KIADB Industrial Area, Nanjangudu, Karnataka, India – 571302
- IndustryHealthcare, Preventive Health Supplements, Ayurvedic Products & Services
To see the full contact details of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Supreem Pharmaceuticals Mysore operates one associated brand: Supreem Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures stabilized vitamins, minerals, and herbal extracts for food, pharma, and beauty sectors. | supreempharma.in |
Business activity
The main business activity of Supreem Pharmaceuticals Mysore is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Financials of Supreem Pharmaceuticals Mysore Private Limited
FY 2025 filings availableSupreem Pharmaceuticals Mysore Private Limited reported revenue of ₹82.17 Cr (up 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 21% growth in the latest year. EBITDA rose 384% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹7.24 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.28 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.8% | ||||
| Net Profit Margin | 2.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Board of directors of Supreem Pharmaceuticals Mysore Private Limited
Supreem Pharmaceuticals Mysore has 4 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Geetha Sadananda Nagaraja Rao | Whole-Time Director | 22 Jan 2008 | 18 Years 9 Months | Current |
| Aditya Sadanand Rao | Whole-Time Director | 10 Jul 2020 | 6 Years 4 Months | Current |
| Amit Sadanand Rao | Whole-Time Director | 10 Jul 2020 | 6 Years 4 Months | Current |
| Sadanand Nagaraja Rao | Managing Director | 16 Aug 1996 | 30 Years 2 Months | Current |
Peer comparison
Supreem Pharmaceuticals Mysore Private Limited is compared with the 5 companies closest to it by revenue in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nagarjuna Herbal Concentrates Ltd | ₹83.43 Cr (FY 2025) | 1.0% | Thodupuzha, Kerala, India | |||
| Abhilash Chemicals and Pharmaceuticals Private Limited | ₹82.45 Cr (FY 2025) | -16.0% | Madurai, Tamil Nadu, India | |||
| Maxheal Pharmaceuticals (India) Limited | ₹82.41 Cr (FY 2024) | 10.0% | Mumbai, Maharashtra, India | |||
| Supreem Pharmaceuticals Mysore Private Limitedthis company | ₹82.17 Cr (FY 2025) | ₹2.28 Cr | 2.8% | 21.0% | 145 | Nanjangudu, Karnataka, India |
| Indian Drugs and Pharmaceuticals Limited | ₹81.46 Cr (FY 2015) | 7.0% | Gurgaon, Haryana, India | |||
| Adroit Pharmaceuticals Private Limited | ₹80.51 Cr (FY 2024) | 2.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Auditor
Supreem Pharmaceuticals Mysore Private Limited is audited by PADIVAL AND ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PADIVAL AND ASSOCIATES | FY 2023 | 012713S |
Shareholding
The shareholding of Supreem Pharmaceuticals Mysore Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Jul 2023 | 100788923 | Axis Bank Limited | ₹5.94 Cr | Open | |
| 09 Oct 2013 | 10453545 | Karnataka State Financial Corporation | ₹8.3 Cr | Open | |
| 21 Nov 2007 | 10081897 | State Bank of India | ₹29.65 Cr | Open | |
| 20 Sep 2002 | 80040389 | State Bank of India | ₹35.25 Lakh | Open | |
| 04 Mar 2015 | 10566618 | Karnataka State Financial Corporation | ₹2 Cr | Satisfied |
To see the full charge records of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Total charge records: 7 View all charges
Deals & funding
Supreem Pharmaceuticals Mysore Private Limited has 15 deals on record (8 secondary share transfers, 4 rights issues, 3 funding rounds), with disclosed funding of ₹1.85 Cr; the latest was in March 2024.
Deals on record (5 of 15)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Rights issue | ₹50 Lakh | Investors: 2 individuals |
| Sep 2020 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Natural Capsules Limited |
| Sep 2016 | Rights issue | ₹3.68 Cr | Investors: Natural Capsules Limited , 3 individuals |
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: Natural Capsules Limited Seller: an individual |
| Aug 2015 | Secondary share transfer | Undisclosed | Buyer: Natural Capsules Limited , an individual Seller: 3 individuals |
To see the full deal history of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Supreem Pharmaceuticals Mysore Private Limited has 11 court cases on record: 8 filed by Supreem Pharmaceuticals Mysore, 3 filed against it. 1 case is pending and 10 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 11 | 3 | 1 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, MYSURU, Karnataka | Civil suit | Filed by the company against M/S Nestor Pharmaceuticals Ltd | Disposed |
| District court, MYSURU, Karnataka | Civil suit | Filed by the company against M/S Shubham Enterprises | Pending |
| District court, MYSURU, Karnataka | Civil suit | Filed by the company against an individual | Disposed |
| District court, MYSURU, Karnataka | Court case (Comp 33 A) | Filed against the company by an individual | Disposed |
| District court, MYSURU, Karnataka | Court case (Ref) | Filed against the company by individuals | Disposed |
To see the full case history of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Supreem Pharmaceuticals Mysore Private Limited has 6 MSME Form 1 returns on record between 2019 and 2024, listing 69 overdue payments to 21 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 21)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| A Star World | |||
| an individual supplier | |||
| an individual supplier | |||
| Euro Tech Pack - Hosur | |||
| Pci Pest Control Private Limited |
To see the full MSME payment records of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Supreem Pharmaceuticals Mysore Private Limited has a workforce of 145 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 145 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
GST
Supreem Pharmaceuticals Mysore has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AABCC9895R1ZF | Karnataka | Active | 01 Jul 2017 |
| 27AABCC9895R1ZJ | Maharashtra | Active | 01 Jul 2017 |
| 07AABCC9895R1ZL | Delhi | Active | 09 May 2022 |
To see the full GST registrations and return filing status of Supreem Pharmaceuticals Mysore Private Limited, buy the company report.
Recent activity
Supreem Pharmaceuticals Mysore Private Limited has 7 board changes on record since 1996: 4 appointments and 3 cessations. The latest: Sunil Mundra Laxminarayana ceased to be Director on 31 Aug 2020.
12 earlier events are in the company report.
Frequently asked questions
Supreem Pharmaceuticals Mysore is an active private limited company based in Nanjangudu, Karnataka, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 16 August 1996 (30+ years old) and is registered under CIN U24231KA1996PTC020988.
Supreem Pharmaceuticals Mysore has 4 current directors:
- Sadanand Nagaraja Rao - Managing Director
- Geetha Sadananda Nagaraja Rao - Whole-Time Director
- Aditya Sadanand Rao - Whole-Time Director
- Amit Sadanand Rao - Whole-Time Director
The latest financial statements of Supreem Pharmaceuticals Mysore on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Supreem Pharmaceuticals Mysore is 29AABCC9895R1ZF, registered in Karnataka. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 27AABCC9895R1ZJ (Maharashtra), 07AABCC9895R1ZL (Delhi).
The CIN (Corporate Identification Number) of Supreem Pharmaceuticals Mysore is U24231KA1996PTC020988. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Supreem Pharmaceuticals Mysore has 11 court cases on record: 8 filed by the company and 3 filed against it. 1 is pending.
Supreem Pharmaceuticals Mysore was incorporated on 16 August 1996, making it 30+ years old. It is registered with the Registrar of Companies, Bangalore.
Supreem Pharmaceuticals Mysore has 15 deals on record (8 secondary share transfers, 4 rights issues, 3 funding rounds), with disclosed funding of ₹1.85 Cr; the latest was in March 2024.
The peers of Supreem Pharmaceuticals Mysore by revenue are Nagarjuna Herbal Concentrates Ltd, Abhilash Chemicals and Pharmaceuticals Private Limited, Maxheal Pharmaceuticals (India) Limited, Indian Drugs and Pharmaceuticals Limited, Adroit Pharmaceuticals Private Limited, all in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sunil Mundra Laxminarayana ceased to be Director on 31 Aug 2020. Aditya Sadanand Rao was appointed as Whole-Time Director on 10 Jul 2020. Amit Sadanand Rao was appointed as Whole-Time Director on 10 Jul 2020. Supreem Pharmaceuticals Mysore has 7 board changes on record in total.
Supreem Pharmaceuticals Mysore has 6 MSME Form 1 returns on record between 2019 and 2024, listing 69 overdue payments to 21 micro and small suppliers. The latest return was filed on 24 Apr 2024.
Supreem Pharmaceuticals Mysore can be reached through the website supreempharma.in. Its registered office is in Nanjangudu, Karnataka, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
